Is 99mTc-Sestamibi Scintimammography Complementary to Conventional Mammography for Detecting Breast Cancer in Patients with Palpable Masses?

The aim of this trial was to evaluate in developing countries from different regions the diagnostic performance of 99mTc-sestamibi scintimammography (SM) in palpable breast lesions and to ver-ify the clinical usefulness of a joint evaluation with mammogra-phy and SM. Methods: From 10 countries, a total of 238 pa-tients with palpable breast masses (n 5 245) were included in this prospective multicenter trial. Prone SM was performed 10 min and 60–90 min (157 patients) after injection using an isotime acquisition of 10 min. Mammography was assessed by the same dedicated imaging radiologist according to breast imag-ing reporting and data system (BI-RADS) categories for malig-nancy and breast density. Masked SM findings and mammog-raphy findings were checked for a correlation with histopathology findings for excisional biopsy samples. Diagnos-tic values for breast cancer detection were calculated per le